Guggenheim Reaffirms “Buy” Rating for Compass Therapeutics (NASDAQ:CMPX)

Guggenheim reaffirmed their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX) in a report published on Wednesday morning,Benzinga reports. The brokerage currently has a $12.00 target price on the stock.

Other analysts also recently issued research reports about the company. D. Boral Capital reiterated a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a research report on Tuesday. Jefferies Financial Group raised their price objective on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, February 10th. Wedbush reaffirmed an “outperform” rating and set a $8.00 price objective on shares of Compass Therapeutics in a report on Tuesday. Leerink Partners raised Compass Therapeutics from a “market perform” rating to an “outperform” rating and increased their target price for the company from $4.00 to $6.00 in a research note on Wednesday. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Compass Therapeutics in a report on Wednesday, January 8th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $11.63.

Compass Therapeutics Trading Down 24.6 %

Compass Therapeutics stock opened at $1.69 on Wednesday. Compass Therapeutics has a 1-year low of $0.77 and a 1-year high of $4.08. The firm has a market capitalization of $233.70 million, a PE ratio of -4.57 and a beta of 1.19. The firm’s 50 day simple moving average is $2.81 and its 200 day simple moving average is $2.11.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Research analysts forecast that Compass Therapeutics will post -0.36 earnings per share for the current year.

Institutional Investors Weigh In On Compass Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Intech Investment Management LLC bought a new position in Compass Therapeutics during the 3rd quarter worth approximately $30,000. Tower Research Capital LLC TRC grew its holdings in shares of Compass Therapeutics by 298.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock worth $25,000 after purchasing an additional 12,917 shares during the last quarter. Independent Advisor Alliance purchased a new position in shares of Compass Therapeutics in the fourth quarter worth $26,000. BNP Paribas Financial Markets bought a new stake in Compass Therapeutics during the 4th quarter valued at $27,000. Finally, XTX Topco Ltd purchased a new stake in Compass Therapeutics during the 3rd quarter valued at $37,000. Institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.